Access to financial results conference call
Rehovot, Israel – November 8, 2017 — Kamada Ltd. (NASDAQ and TASE: KMDA), a plasmaderived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the third quarter ended September 30, 2017, prior to the open of the U.S. financial markets on Monday, November 13.
Kamada management will host an investment community conference call on Monday, November
13, at 8:30am Eastern Time, to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-741-4248 (from within the U.S.), 1 80 925 8243 (from Israel), or 719-325-4754 (International) and entering the conference identification number: 2675273. The call will also be webcast live on the Internet on the Company's website at www.kamada.com.
A replay of the call will be accessible two hours after its completion through November 27 by
dialing 844-512-2921 (from within the U.S.) or 412-317-6671 (from outside the U.S.) and entering
the conference identification number: 2675273. The call will also be archived for 90 days on the
Company's website at www.kamada.com.
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a
commercial product portfolio and a robust late-stage product pipeline. The Company uses its
proprietary platform technology and know-how for the extraction and purification of proteins
from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as
well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma
with known and newly-discovered therapeutic roles given its immunomodulatory, antiinflammatory,
tissue-protective and antimicrobial properties. The Company's flagship product is
GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved
by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a
strategic partnership with Baxalta (now part of Shire plc) and in other counties through local
distributors. In addition to GLASSIA®, Kamada has a product line of seven other
pharmaceutical products administered by injection or infusion, that are marketed through
distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries
in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in
development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In
addition, Kamada's intravenous AAT is in development for other indications, such as type-1
diabetes, GvHD and prevention of lung transplant rejection. Kamada's rabies immune globulin
(Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection
in August 2017. Kamada also leverages its expertise and presence in the plasma-derived protein
therapeutics market by distributing more than 10 complementary products in Israel that are
manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as
amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are statements that are not historical facts, such as statements
regarding assumptions and results related to financial results forecast, commercial results, timing
and results of clinical trials and EMA and U.S. FDA submissions and authorizations. Forwardlooking statements are based on Kamada's current knowledge and its present beliefs and
expectations regarding possible future events and are subject to risks, uncertainties and
assumptions. Actual results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of several factors including, but not
limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EM
approval process, additional competition in the AATD market, further regulatory delays,
prevailing market conditions, and the impact of general economic, industry or political
conditions in the U.S., Israel or otherwise. The forward-looking statements made herein speak
only as of the date of this announcement and Kamada undertakes no obligation to update
publicly such forward-looking statements to reflect subsequent events or circumstances, except
as otherwise required by law.
CONTACTS:
Gil Efron
Deputy CEO & Chief Financial Officer
IR@kamada.com
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com